Treating infections

Israel’s AtoxBio Ltd. has raised $3.5 million to finance a Phase II clinical trial for the effectiveness of its drug AB 103 for necrotizing soft tissue infections (NSTI). The drug has been granted fast-track orphan status by the US Food and Drugs Administration, as there are no alternative approved treatments.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000708115&fid=1725

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *